Septerna, Inc. (NASDAQ: SEPN) is capturing the attention of investors in the healthcare sector, particularly within the biotechnology industry. With a market capitalization of $971.51 million, this South San Francisco-based..
Tourmaline Bio, Inc. (NASDAQ: TRML), a dynamic player in the biotechnology sector, stands out with its niche focus on developing treatments for immune and inflammatory diseases. Headquartered in New York..
For investors interested in the evolving cannabis market, Tilray Brands, Inc. (NASDAQ: TLRY) presents an intriguing opportunity with a potential upside of 20.50%. This Canadian-based company, with a market capitalization..
AngioDynamics, Inc. (NASDAQ: ANGO), a notable player in the healthcare sector, is capturing investor attention with a compelling potential upside of 54.17%. As a specialist in medical instruments and supplies,..
Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the healthcare sector, has captured investor attention with its diverse portfolio of preparedness and response solutions for public health threats. Operating..
Investors with an eye on the healthcare sector may find Myriad Genetics, Inc. (NASDAQ: MYGN) worth a deeper look. The company, based in Salt Lake City, Utah, specializes in molecular..
Treace Medical Concepts, Inc. (NASDAQ: TMCI) stands out in the medical devices industry with a promising potential upside of 23.96%, making it a noteworthy candidate for investors seeking growth in..
Castle Biosciences, Inc. (NASDAQ: CSTL) is capturing investor attention with a compelling 47% potential upside based on its average target price. As a key player in the healthcare sector, specializing..
Semler Scientific, Inc. (NASDAQ: SMLR), a prominent player in the healthcare sector, particularly within the medical devices industry, is capturing investor attention with a striking potential upside of 230.99%. With..
Owens & Minor, Inc. (NYSE: OMI) stands as a significant player in the healthcare sector, specifically within medical distribution. With a market capitalization of $406.3 million, this Glen Allen, Virginia-based..
Investors looking to explore opportunities within the healthcare sector should pay close attention to SIGA Technologies Inc. (NASDAQ: SIGA). This commercial-stage pharmaceutical company, headquartered in New York, focuses on the..
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is capturing attention in the biotechnology sector, not only for its innovative approach to tackling cancer but also for the impressive potential upside its stock..
Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company, is capturing attention with its impressive projected upside of nearly 196.70%. Specializing in developing treatments for cancer, particularly acute leukemias and..
Oculis Holding AG (OCS), a Switzerland-based biopharmaceutical company, has caught the attention of investors with its promising portfolio in ophthalmic drug development. Operating within the healthcare sector and more specifically..
Investors with an eye on the healthcare sector might find AxoGen, Inc. (NASDAQ: AXGN) an intriguing candidate for their portfolios. Specializing in medical devices, this Florida-based company has carved a..
Cel-Sci Corporation (NYSE American: CVM) has caught the attention of investors with its staggering potential upside of 1,902.39%, as suggested by recent analyst ratings. This clinical-stage biotechnology company, headquartered in..
Theravance Biopharma, Inc. (NASDAQ: TBPH) is capturing investor interest with its notable potential upside of 41.44%, a compelling figure for those looking to delve into the dynamic biotechnology sector. With..
Ginkgo Bioworks Holdings, Inc. (NASDAQ: DNA), a prominent player in the biotechnology sector, is drawing considerable attention from investors due to its innovative approach to cell programming and its potential..
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is making waves in the biotechnology sector with its focus on developing breakthrough treatments for severe autoimmune and inflammatory diseases. With a market capitalization of..
Syndax Pharmaceuticals, Inc. (SNDX) has recently caught the attention of investors with a compelling potential upside of 156.76%, as indicated by its average target price of $37.69 against a current..
